Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer.
Journal Information
Full Title: Cancer Manag Res
Abbreviation: Cancer Manag Res
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Disclosure The authors have no conflicts of interest to declare in this work."
Funding Disclosure
Evidence found in paper:
"This research was supported by the Natural Science Foundation of Shandong Province, (Grant number ZR2019LZL012), Jinan Clinical Medical Science and Technology Innovation Plan (Grant number 202019043), National Natural Science Foundation of China (Grant number 8217102892), The Key Research and Development Program of Shandong (Major Science & Technology Innovation Project) (2021SFGC0501), and Start-up fund of Shandong Cancer Hospital (2022-B14)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025